These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 12920570

  • 21. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ.
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1326-34. PubMed ID: 17162215
    [Abstract] [Full Text] [Related]

  • 22. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH, Lee JH, Lee JH, Kim DY, Kim SH, Shin HJ, Lee YS, Kang YA, Seol M, Ryu SG.
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [Abstract] [Full Text] [Related]

  • 23. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ, Chung JS, Cho GJ, Yang DH, Lee JJ, Kim YK, Kim HJ.
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [Abstract] [Full Text] [Related]

  • 24. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
    Morecki S, Gelfand Y, Nagler A, Or R, Naparstek E, Varadi G, Engelhard D, Akerstein A, Slavin S.
    Bone Marrow Transplant; 2001 Aug; 28(3):243-9. PubMed ID: 11535991
    [Abstract] [Full Text] [Related]

  • 25. Cytomegalovirus infections following umbilical cord blood transplantation using reduced intensity conditioning regimens for adult patients.
    Matsumura T, Narimatsu H, Kami M, Yuji K, Kusumi E, Hori A, Murashige N, Tanaka Y, Masuoka K, Wake A, Miyakoshi S, Kanda Y, Taniguchi S.
    Biol Blood Marrow Transplant; 2007 May; 13(5):577-83. PubMed ID: 17448917
    [Abstract] [Full Text] [Related]

  • 26. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
    Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K, Ohta K, Hino M.
    Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
    [Abstract] [Full Text] [Related]

  • 27. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution.
    Nakai K, Mineishi S, Kami M, Saito T, Hori A, Kojima R, Imataki O, Hamaki T, Yoshihara S, Ohnishi M, Kim SW, Ando T, Fumitoh A, Kanda Y, Makimoto A, Tanosaki R, Kanai S, Heike Y, Ohnishi T, Kawano Y, Wakasugi H, Takaue Y.
    Transplantation; 2003 Jun 27; 75(12):2135-43. PubMed ID: 12829926
    [Abstract] [Full Text] [Related]

  • 28. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation.
    Seidel MG, Fritsch G, Matthes-Martin S, Lawitschka A, Lion T, Pötschger U, Rosenmayr A, Fischer G, Gadner H, Peters C.
    Haematologica; 2005 Oct 27; 90(10):1405-14. PubMed ID: 16219578
    [Abstract] [Full Text] [Related]

  • 29. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation.
    Saito T, Kanda Y, Nakai K, Kim SW, Arima F, Kami M, Tanosaki R, Tobinai K, Wakasugi H, Heike Y, Mineishi S, Takaue Y.
    Bone Marrow Transplant; 2003 Sep 27; 32(6):601-8. PubMed ID: 12953133
    [Abstract] [Full Text] [Related]

  • 30. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA, Carter SL, Freifeld AG, High KP, Godder KT, Papanicolaou GA, Mendizabal AM, Wagner JE, Yanovich S, Kernan NA.
    Biol Blood Marrow Transplant; 2007 Dec 27; 13(12):1487-98. PubMed ID: 18022579
    [Abstract] [Full Text] [Related]

  • 31. Risk factors for late cytomegalovirus infection after allogeneic stem cell transplantation using HLA-matched sibling donor: donor lymphocyte infusion and previous history of early CMV infection.
    Kim DH, Kim JG, Lee NY, Sung WJ, Sohn SK, Suh JS, Lee KS, Lee KB.
    Bone Marrow Transplant; 2004 Jul 27; 34(1):21-7. PubMed ID: 15133483
    [Abstract] [Full Text] [Related]

  • 32. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection.
    Qamruddin AO, Oppenheim BA, Guiver M, Mutton KJ, Chopra R.
    Bone Marrow Transplant; 2001 Feb 27; 27(3):301-6. PubMed ID: 11277178
    [Abstract] [Full Text] [Related]

  • 33. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 34. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group.
    George B, Kerridge IH, Gilroy N, Huang G, Hertzberg MS, Bradstock KF, Gottlieb DJ.
    Transpl Infect Dis; 2012 Apr 01; 14(2):141-8. PubMed ID: 22283838
    [Abstract] [Full Text] [Related]

  • 35. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
    Faber E, Koza V, Vitek A, Mayer J, Sedlacek P, Zak P, Zapletalova J, Benesova K, Krejcova H, Steinerova K, Maresova I, Cetkovsky P, Czech National Hematopoietic Stem Cell Transplantation Registry.
    Neoplasma; 2007 Apr 01; 54(5):443-6. PubMed ID: 17688375
    [Abstract] [Full Text] [Related]

  • 36. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
    Schetelig J, Bornhäuser M, Kiehl M, Schwerdtfeger R, Kröger N, Runde V, Zabelina T, Held TK, Thiede C, Fauser AA, Beelen D, Zander A, Ehninger G, Siegert W, Cooperative German Transplant Study Group.
    Bone Marrow Transplant; 2004 Mar 01; 33(5):483-90. PubMed ID: 14716342
    [Abstract] [Full Text] [Related]

  • 37. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients.
    Heining C, Spyridonidis A, Bernhardt E, Schulte-Mönting J, Behringer D, Grüllich C, Jakob A, Bertz H, Finke J.
    Bone Marrow Transplant; 2007 May 01; 39(10):613-22. PubMed ID: 17384658
    [Abstract] [Full Text] [Related]

  • 38. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.
    Blood Cells Mol Dis; 2008 May 01; 40(1):13-9. PubMed ID: 17869547
    [Abstract] [Full Text] [Related]

  • 39. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS.
    Pediatr Blood Cancer; 2007 Sep 01; 49(3):306-12. PubMed ID: 16972242
    [Abstract] [Full Text] [Related]

  • 40. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Iravani M, Evazi MR, Mousavi SA, Shamshiri AR, Tavakoli M, Ashouri A, Samiee S, Chahardovali B, Alimoghaddam K, Ghaffari SH, Ghavamzadeh A.
    Bone Marrow Transplant; 2007 Jul 01; 40(2):105-10. PubMed ID: 17468775
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.